<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626023</url>
  </required_header>
  <id_info>
    <org_study_id>TH-SC 2.0</org_study_id>
    <nct_id>NCT05626023</nct_id>
  </id_info>
  <brief_title>A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety and Tolerability of Human TH-SC01 Cell Injection for the Treatment of Perianal Fistulas in Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Topcel-KH Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Topcel-KH Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of human TH-SC01 cell&#xD;
      injection for the treatment of perianal fistulas in Crohn's Disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 1, single-arm, safety and tolerability study of human TH-SC01 cell&#xD;
      injection for perianal fistulas in Crohn's Disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2022</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity and incidence of adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>Severity and incidence of adverse events within 28 days after adiministration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>84 days</time_frame>
    <description>Exploration of dose-limiting toxicity (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>84 days</time_frame>
    <description>Exploration of maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perianal fistula healing</measure>
    <time_frame>84 days</time_frame>
    <description>Change from baseline in Van Assche Score by MRI test. The score range was from 0 to 25. Higher score means more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's Disease Activity Index (CDAI) score</measure>
    <time_frame>84 days</time_frame>
    <description>Change from baseline in the Crohn's Disease Activity Index (CDAI) score. Higher score means more severe disease and especially severe disease was defined as a value of greater than 450.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perianal Disease Activity Index (PDAI)</measure>
    <time_frame>84 days</time_frame>
    <description>Change from baseline in Perianal Disease Activity Index (PDAI). Total score ranges from 0 to 20. Higher score means more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Bowel Disease Questionnaire（IBDQ）score</measure>
    <time_frame>84 days</time_frame>
    <description>Change from baseline in IBDQ score. Total score ranges from 32 to 224. Higher score means better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score</measure>
    <time_frame>84 days</time_frame>
    <description>Change from baseline in pain score (VAS score).Total score ranges from 0 to 10. Higher score means more pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anal sphincter function：Wexner incontinence score</measure>
    <time_frame>84 days</time_frame>
    <description>Change from baseline in anal sphincter function, Wexner incontinence score,Total score ranges from 0 to 20. Higher score means more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anal sphincter function： rectal pressure</measure>
    <time_frame>84 days</time_frame>
    <description>Change from baseline in rectal pressure，In healthy people, the pressure ranges from 60 to 150mmHg, with the internal sphincter pressure accounts for about 80% and external sphincter pressure accounts for 20%.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Perianal Fistula</condition>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Human TH-SC01 cell injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of 0.6×10^7, 1.2×10^8, 1.8×10^8 cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human TH-SC01 cell injection</intervention_name>
    <description>Single injection of human TH-SC01 cell injection</description>
    <arm_group_label>Human TH-SC01 cell injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent.&#xD;
&#xD;
          2. Subjects with Crohn's disease diagnosed at least 6 months earlier according to the&#xD;
             Chinese Consensus Opinion on the Diagnosis and Treatment of Inflammatory Bowel&#xD;
             Diseases (Beijing, 2018).&#xD;
&#xD;
          3. Subjects with active perianal fistula and non active luminal CD defined by a CDAI ≤&#xD;
             200.&#xD;
&#xD;
          4. Subjects with perianal fistula confirmed by clinical assessment and MRI.&#xD;
&#xD;
          5. Subjects aged between 18 and 70, both male and female.&#xD;
&#xD;
          6. All subjects and their partners were not planning to have a child from screening to&#xD;
             the end of the trial and agreed to use effective non-drug contraception during the&#xD;
             trial.&#xD;
&#xD;
          7. Subjects failed to respond to adequate treatment with any of the conventional&#xD;
             antibiotics, immunomodulatory drugs (including steroids), anti-tumor necrosis factor-α&#xD;
             (TNF-α) monoclonal antibodies and other biological agents.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with active infection evaluated by the investigator.&#xD;
&#xD;
          2. Subjects with Crohn's disease requiring immediate therapy.&#xD;
&#xD;
          3. Subjects with abscess or collections &gt;2 cm.&#xD;
&#xD;
          4. Subjects with rectal and/or anal stenosis and/or active proctitis.&#xD;
&#xD;
          5. Subjects who treated with systemic steroids in the 4 weeks prior to stem cells&#xD;
             administration.&#xD;
&#xD;
          6. Subjects with abnormal laboratory results: liver function: total bilirubin &gt;=1.5 ×&#xD;
             ULN, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &gt;=2 ×&#xD;
             ULN; renal function: creatinine clearance below 60 mL/minute calculated using&#xD;
             Cockcroft-Gault formula or by serum creatinine &gt;=1.5 × upper limit of normal (ULN).&#xD;
&#xD;
          7. Subjects with malignant tumors or a history of malignant tumors.&#xD;
&#xD;
          8. Subjects with severe, progressive, uncontrolled hepatic, hematological,&#xD;
             gastrointestinal (except Crohn's disease), endocrine, pulmonary, cardiac,&#xD;
             neurological, psychiatric, or cerebral diseases.&#xD;
&#xD;
          9. Serum virology test (HBeAg, HCV antibody, HIV antibody, Treponema pallidum antibody)&#xD;
             positive.&#xD;
&#xD;
         10. Subjects allergic to gentamicin sulfate, anesthetics or contrast media.&#xD;
&#xD;
         11. Subjects allergic to MRI contrast.&#xD;
&#xD;
         12. Subjects who has received stem cells in a previous clinical study or as a therapeutic&#xD;
             agent.&#xD;
&#xD;
         13. Subjects who has major surgery or severe trauma within 6 months prior to the screening&#xD;
             period.&#xD;
&#xD;
         14. Subjects who has received any investigational drug within 3 months prior to the&#xD;
             screening.&#xD;
&#xD;
         15. Subjects deemed inappropriate by the investigator to participate in this clinical&#xD;
             trial.&#xD;
&#xD;
         16. The female participant who is pregnant, or is lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhaoshen Li, Dr.</last_name>
    <phone>021-81873241</phone>
    <email>zhaoshen-li@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Zhang, Dr.</last_name>
    <phone>021-31162333</phone>
    <email>chyyzhl@163.com</email>
  </overall_contact_backup>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 26, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>November 15, 2022</last_update_submitted>
  <last_update_submitted_qc>November 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Rectal Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

